Literature DB >> 163165

Plasma adenosine 3':5'-cyclic monophosphate response to glucagon in thyroid disease.

R S Elkeles, J H Lazarus, K Siddle, A K Campbell.   

Abstract

1. The plasma adenosine 3':5'-cyclic monophosphate (cyclic AMP) response to intravenously administered glucagon has been studied in nine hyperthyroid, five hypothyroid and ten euthyroid patients. 2. Concentrations of the nucleotide rose to a peak at 15 min and declined to near basal values by 120 min, the response being greatest in hyperthyroid and least in hypothyroid subjects. The mean peak concentrations were 1028 nmol/1 in the hyperthyroid group, 252 nmol/1 in the hypothyroid group and 534 nmol/1 in the euthyroid group. 3. These results could not be accounted for by differences in serum insulin response. 4. It is suggested that the response of plasma cyclic AMP to glucagon may serve as an index of tissue thyroid status.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 163165     DOI: 10.1042/cs0480027

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN: 0301-0538


  4 in total

1.  Investigation of the usefulness of the plasma adenosine 3' 5' - cyclic monophosphate response to glucagon in thyroid disease.

Authors:  S Mac Neil; G N Hendy; H Amirrasooli; P R Daggett; S Tomlinson
Journal:  J Endocrinol Invest       Date:  1980 Oct-Dec       Impact factor: 4.256

2.  Plasma cyclic adenosine-3', 5'-monophosphate response to glucagon in patients with liver disease.

Authors:  T F Davies; K Prudhoe; A P Douglas
Journal:  Br Med J       Date:  1976-04-17

3.  Plasma and urine cyclic nucleotide levels in patients with hyperthyroidism and hypothyroidism.

Authors:  M Peracchi; F Bamonti-Catena; L Lombardi; E Reschini; V Toschi; A T Maiolo; E E Polli
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

Review 4.  The impact of peptide hormone receptor research on clinical medicine.

Authors:  T F Davies
Journal:  J R Coll Physicians Lond       Date:  1978-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.